Jun 30, 2005 (financialwire.net via COMTEX) --

June 30, 2005 (FinancialWire) (Investrend Research Syndicate) MIV Therapeutics (OTCBB: MIVT) gained 11.77% intraday to $0.57 before closing at $0.51 on volume of 435,318, almost twice the average volume of 279,442 after Ernest C. Schlotter, a senior analyst with InvesTrend affiliate SISM Research reiterated his Speculative Buy/4 rating for MIV Therapeutics (OTCBB: MIVT) with a 12-month price target of $1.50.

Schlotter noted in a Research Note that MIVT had announced that its HAp-coated cardiovascular stents demonstrate excellent safety and feasibility at 3-month follow-up after porcine implantation, and that the company underwent successful major business developments and reached significant milestones during the first half of 2005.

Very importantly, independent studies from Japan confirmed HAp's exceptional biocompatibility; biocompatibility is a key functional requirement for any coating technology. MIVT has also successfully completed preliminary porcine coronary implantation trials on its HAp coated stents, and it has to be noted that such biocompatibility of coated stainless steel surfaces has rarely been found in polymer stent coatings currently dominating the field.

Schlotter said; "Just when MIVT's HAp coating has demonstrated excellent biocompatibility, a report in the May 4, 2005 edition of the Journal of the American Medical Association said that a higher-than-expected rate of serious complications occurred among patients who had received either J&J's CYPHER stent, or Boston Scientific's TAXUS. Researchers found that late stage thrombogenicity and restenosis aren't the only problems associated with polymers. Polymer coated stents cause allergic reactions and other, serious side effects".

MIVT's final porcine trials are now in progress, and are expected to be successfully completed in 3Q2005, with human clinical trials possibly beginning as early as the end of this year. SISM Research believes that medical device companies simply can't overlook MIVT's technology as the company heads toward these clinical trials, and as more and more studies point to the need for 100% biocompatibility.

SISM also mentioned the planned acquisition of Sahajanand Medical Technologies and Schlotter said, "If the deal is completed, both companys' synergy would position MIVT to become a major commercial player in the rapidly growing market for cardiac and other types of implantable medical devices."

The company also augmented its proprietary technology with the recent acquisition of SagaX Medical Technologies, which is leading the way in the development of an Aortic Embolic Protection Device (AEPD), that filters blood in the aorta and prevents cardioembolic stroke, a dangerous, and sometimes deadly, complication of even minimally invasive heart procedures. The company has already commenced preclinical trials and this technology offers new business opportunities for MIVT, as the market for AEPDs is estimated to exceed approximately 2 billion by 2009. SISM Research has outlined an investment thesis that shows quite clearly that MIVT is undervalued and therefore has reaffirmed its Speculative Buy/4 Rating for the stock of MIV Therapeutics with a 12-month target price of $1.50.

SISM Research, based in Zurich, Switzerland, is a private investment research firm offering high-quality, independent, fundamental research on public companies since 1995. SISM writes, publishes and distributes research coverage, in both English and German, on micro- to small-cap public companies trading on the OTC Bulletin Board, NASDAQ and AMEX. This coverage is geared toward institutional and individual investors in both North America and in German-speaking Europe, a market that represents more than 100 million people. SISM Research is a content provider to Thomson Financials OneAnalytics/FirstCall, to Multex, and InvesTrend. Both SISM Research and InvesTrend Research subscribe to the "Standards for Independent Research Providers."

MIV Therapeutics is paying SISM Research $1,750 per month over a two-year period solely to ensure independent coverage.

Complete information about any company enrolled in an Investrend shareholder empowerment platform, including those of its affiliates and independent analysts and webcasters, including disclosures and disclaimers, is available at the company's InvestorPower page at http://www.investrend.com/company/list.asp?sPathParam=yes , and on each report and press release, and investors are advised to read those disclosures carefully before trading in the equities of any enrolled company.

For alerts, write contact@investrend.com with "MIVT" in the subject line.

For up-to-the-minute news, features and links click on http://www.financialwire.net

FinancialWire is an independent, proprietary news service of Investrend Information, a division of Investrend Communications, Inc. It is not a press release service and receives no compensation for its news or opinions. Other divisions of Investrend, however, provide shareholder empowerment platforms such as forums, independent research and webcasting. For more information or to receive the FirstAlert daily summary of news, commentary, research reports, webcasts, events and conference calls, click on http://www.investrend.com/contact.asp

The FinancialWire NewsFeed is now available in multiple formats to your site or desktop, free. Click on: http://www.investrend.com/XmlFeeds?level=268

http://www.financialwire.net